Production (Stage)
Mydecine Innovations Group Inc.
MYCO
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -42.89% | -64.39% | -39.23% | -65.81% | -83.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.14% | -179.88% | 82.09% | -2.41% | -83.38% |
| Operating Income | 44.14% | 179.88% | -82.09% | 2.41% | 83.38% |
| Income Before Tax | 72.37% | 136.16% | -65.51% | -4.05% | 90.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.37% | 136.16% | -65.51% | -4.05% | 90.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.37% | 136.16% | -65.51% | -4.05% | 90.26% |
| EBIT | 44.14% | 179.88% | -82.09% | 2.41% | 83.38% |
| EBITDA | -- | 179.97% | -82.07% | 2.37% | 83.42% |
| EPS Basic | 75.71% | 129.07% | 23.13% | 57.18% | 96.64% |
| Normalized Basic EPS | 60.23% | 117.62% | 22.92% | 57.08% | 91.35% |
| EPS Diluted | 75.71% | 129.07% | 23.13% | 57.18% | 96.64% |
| Normalized Diluted EPS | 60.23% | 117.62% | 22.92% | 57.08% | 91.35% |
| Average Basic Shares Outstanding | 14.78% | 24.60% | 114.81% | 143.26% | 189.87% |
| Average Diluted Shares Outstanding | 14.78% | 24.60% | 114.81% | 143.26% | 189.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |